Novartis has recalled a single lot of Diovan, its brand-name version of the blood pressure drug valsartan, after the tablets failed a laboratory test that measures how they break down in the body.
The recall covers Diovan 160 mg tablets in 90-count bottles, lot number AV5913C, with an expiration date of June 2027. Novartis initiated the action on August 4, and the Food and Drug Administration classified it as a Class II recall on August 7, publishing the entry in its weekly enforcement report on August 8. The tablets were manufactured by Patheon Manufacturing Services in Greenville, North Carolina, and distributed by Novartis Pharmaceuticals Corporation in Hanover, New Jersey.
The reason listed is failed dissolution specifications. That phrase is easy to misread, and getting it right determines what a patient should do. This is not a contamination recall. Nothing foreign was found in the tablets. The concern is that the medication may not be released into the body as intended, which affects how well it works rather than whether it is harmful to swallow.
The Lot Number and the Bottle It Is Printed On
Only one lot is affected. Patients taking Diovan 160 mg should check the bottle their pharmacy dispensed and look for lot AV5913C alongside the June 2027 expiration date. Bottles with a different lot number are not part of this recall, and other strengths of Diovan are not included.
A practical complication: many pharmacies dispense into their own vials rather than handing over the manufacturer's sealed bottle, so the lot number may not be on the container at home. Anyone who cannot find a lot number should call the dispensing pharmacy, which can look it up from the fill record. That call is more reliable than trying to match a label.
Valsartan is among the most widely prescribed cardiovascular medicines in the United States, which is part of why a single-lot recall draws attention. Patients taking generic valsartan from other manufacturers are not affected. Neither are patients on other Diovan strengths or other lots of the same strength.
Dissolution Failures Are About Potency, Not Poison
Dissolution testing measures the amount of active ingredient released from a tablet over a set period under controlled laboratory conditions. A tablet that dissolves too slowly may deliver less drug than intended. The clinical translation for a blood pressure medication is that the dose may be working at less than full strength.
The FDA applies its Class II designation when use of or exposure to a product may cause "temporary or medically reversible adverse health consequences," or when the probability of serious consequences is remote. For a hypertension drug, an underperforming dose over weeks could allow blood pressure to drift upward, which is a real concern but not an acute emergency, and it is reversible once the medication is replaced.
That distinction separates this from the valsartan recalls most patients remember. Beginning in 2018, global recalls pulled many valsartan products after nitrosamine impurities, including NDMA, were found in active ingredient manufactured overseas. Those were contamination recalls involving a probable carcinogen. This one is a manufacturing quality failure at a domestic contract manufacturer, with no impurity reported. Conflating the two would misstate the risk in both directions.
Dissolution failures are also not unusual in this drug class. MedicalDaily has covered a similar dissolution failure affecting more than 11,000 bottles of a blood pressure water pill earlier this summer, and reporting from Cardiovascular Business frames the Diovan action the same way: an effectiveness question rather than a contamination one.
Stopping a Blood Pressure Pill Is the Bigger Risk
The most likely harm from this recall is not the recalled tablets. It is a patient reading a headline, becoming alarmed, and stopping their medication.
Discontinuing an angiotensin II receptor blocker can allow blood pressure to rise, and for patients taking valsartan for heart failure or after a heart attack, an unmanaged interruption carries more risk than finishing a bottle that may be slightly underpotent. No patient should stop taking Diovan on their own because of this notice. The correct sequence is to keep taking the medication, call the pharmacy or prescriber, and arrange a replacement.
Patients on recalled lots can generally exchange the product at the dispensing pharmacy. Anyone worried about cost should ask the pharmacist how a replacement will be handled before assuming a new charge, and can ask the prescriber whether a generic valsartan substitution is appropriate.
People who have been taking from this lot for several weeks may reasonably ask their clinician whether a blood pressure check is worthwhile. That is a low-cost, low-risk step, and home readings taken over several days give a clinician more useful information than a single office measurement. Anyone experiencing severe headache, chest pain, shortness of breath, vision changes, or confusion should seek urgent care rather than waiting for a scheduled appointment, regardless of any recall.
Several things remain unresolved. Neither Novartis nor the FDA has disclosed how many bottles are in the affected lot, how far the dissolution results were out of specification, or what caused the failure at the manufacturing site. It is also unclear how much of the lot had already been dispensed to patients before the recall was initiated, which determines how much is sitting in medicine cabinets rather than on pharmacy shelves. No adverse events have been publicly linked to the lot. Whether the recall expands to additional lots or strengths depends on the company's ongoing quality review, and updates typically appear in the agency's recalls and safety alerts index as the action progresses. Patients holding lot AV5913C should call their pharmacy this week rather than waiting for a notification letter.
Key Questions Answered
Which product is recalled? Diovan 160 mg tablets in 90-count bottles, lot AV5913C, expiring June 2027. No other lots or strengths are included.
Is generic valsartan affected? No. This recall covers only one lot of the brand-name Diovan distributed by Novartis.
What does failed dissolution mean? The tablets did not meet the standard for the amount of active ingredient released over a set time during testing. The medication may be less effective, but it is not contaminated.
Should I stop taking my medication? No. Stopping a blood pressure drug on your own carries more risk than the recall. Keep taking it and contact your pharmacy or prescriber for a replacement.
Is this related to the older valsartan cancer recalls? No. Those involved nitrosamine impurities in the active ingredient. This is a manufacturing quality failure with no impurity reported.
My pharmacy repackaged my pills, and there is no lot number. What now? Call the dispensing pharmacy. It can identify the lot from your fill record.
When should I seek urgent care? Severe headache, chest pain, shortness of breath, vision changes, or confusion warrant immediate evaluation, independent of any recall.
